References
Ali, N. A., O'Brien, J. M., Jr., Blum, W., Byrd, J. C., Klisovic, R. B., Marcucci, G., … Grever, M. R. (2007). Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality. Cancer, 110, 96-102.
Barone, B., Yeh, H., Snyder, C., Peairs, K., Stein, K., Derr, R., … Brancati, F. (2008). Long-term all-cause mortality in cancer patients with preexisting diabetis mellitus: A systematic review and meta-analysis. JAMA, 300, 2754-2764. doi:10.1001/jama.2008.824
Basaria, S. (2008). Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: An inconvenient truth. Journal of Andrology, 29, 534-539.
Basaria, S., Muller, D. C., Carducci, M. A., Egan, J., & Dobs, A. S. (2006). Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer, 106, 581-588.
Baselga, J., Campone, M., Piccart, M., Burris, H. A., III, Rugo, H. S., Sahmoud, T., … Hortobagyi, G. N. (2012). Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. New England Journal of Medicine, 366, 520-529.
Beer, T. M., Ryan, C. W., Venner, P. M., Petrylak, D. P., Chatta, G. S., Ruether, J. D., … Clow, F. W. (2007). Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT investigators. Journal of Clinical Oncology, 25, 669-674.
Bellmunt, J., Szczylik, C., Feingold, J., Strahs, A., & Berkenblit, A. (2008). Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Annals of Oncology, 19, 1387-1392.
Bex, A., Mallo, H., Kerst, M., Haanen, J., Horenblas, S., & de Gast, G. C. (2005). A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor. Cancer Immunology, Immunotherapy, 54, 713-719.
Braga-Basaria, M., Dobs, A. S., Muller, D. C., Carducci, M. A., John, M., Egan, J., & Basaria, S. (2006). Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. Journal of Clinical Oncology, 24, 3979-3983.
Brunello, A., Kapoor, R., & Extermann, M. (2011). Hyperglycemic during chemotherapy for hematologic and solid tumors is correlated with increased toxicity. American Journal of Clinical Oncology, 34, 292-296. doi:10.1097/coc.0b013e3181e1d0c0
Derweesh, I. H., Diblasio, C. J., Kincade, M. C., Malcolm, J. B., Lamar, K. D., Patterson, A. L., … Wake, R. W. (2007). Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU International, 100, 1060-1065.
Feliu, J., Martin, G., Lizon, J., Chacon, J. I., Dorta, J., de Castro, J., … Gonzalez Baron, M. (2001). Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study. Annals of Oncology, 12, 1369-1374.
Feng, J. P., Yuan, X. L., Li, M., Fang, J., Xie, T., Zhou, Y., … Ye, D. W. (2012). Secondary diabetes associated with 5-fluorouracil-based chemotherapy regimens in non-diabetic patients with colorectal cancer: Results from a single centre cohort study. Colorectal Disease, 17, 1463-1318.
Fuji, S., Kim, S., Mori, S., Fukuda, T., Kamiya, S., Yamasaki, S., … Takaue, Y. (2007). Hyperglycemia during the neutropenic period is associated with a poor outcome in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation. Transplantation, 84, 814-820.
Fury, M. G., Sherman, E., Haque, S., Korte, S., Lisa, D., Shen, R., … Pfister, D. (2012). A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 69, 591-598.
Galanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K., Boni, J., … Walsh, D. J. (2005). Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group study. Journal of Clinical Oncology, 23, 5294-5304.
Giovanucci, E., Harlan, D., Archer, M., Bergenstal, R., Gapstur, S., Habel, L., … Yee, D. (2010). Diabetes and cancer: A consensus report. CA: A Cancer Journal for Clinicians, 60, 207-221.
Godbout, J. P., & Glaser, R. (2006). Stress-induced immune dysregulation: implications for wound healing, infectious disease and cancer. Journal of Neuroimmune Pharmacology, 1, 421-427.
Grivennikov, S. I., & Karin, M. (2011). Inflammatory cytokines in cancer: Tumour necrosis factor and interleukin 6 take the stage. Annals of the Rheumatic Diseases, 70(Suppl. 1), i104-i108.
Hakimian, P., Blute, M., Jr., Kashanian, J., Chan, S., Silver, D., & Shabsigh, R. (2008). Metabolic and cardiovascular effects of androgen deprivation therapy. BJU International, 102, 1509-1514.
Hammer, M. J., Casper, C., Gooley, T. A., O'Donnell, P. V., Boeckh, M., & Hirsch, I. B. (2009). The contribution of malglycemia to mortality among allogeneic hematopoietic cell transplant recipients. Biology of Blood and Marrow Transplantation, 15, 344-351.
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., … Motzer, R. J. (2007). Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine, 356, 2271-2281.
Inaba, M., Otani, Y., Nishimura, K., Takaha, N., Okuyama, A., Koga, M., … Kasayama, S. (2005). Marked hyperglycemia after androgen-deprivation therapy for prostate cancer and usefulness of pioglitazone for its treatment. Metabolism, 54, 55-59.
Infante, J. R., Yardley, D. A., Burris, H. A., III, Greco, F. A., Farley, C. P., Webb, C., … Hainsworth, J. D. (2009). Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer. Clinical Breast Cancer, 9, 23-28.
Jenkins, D. J., Kendall, C. W., Augustin, L. S., Franceschi, S., Hamidi, M., Marchie, A., … Axelsen, M. (2002). Glycemic index: Overview of implications in health and disease. American Journal of Clinical Nutrition, 76, 266S-273S.
Katz, A. (2007). Modulation of glucose transport in skeletal muscle by reactive oxygen species. Journal of Applied Physiology, 102, 1671-1676.
Leak, A., Davis, E., Houchin, L., & Mabrey, M. (2009). Diabetes management and self-care education for hospitalized patients with cancer. Clinical Journal of Oncology Nursing, 13, 205-210.
Lee, Y. J., Doliny, P., Gomez-Fernandez, C., Powell, J., Reis, I., & Hurley, J. (2004). Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancers. Clinical Breast Cancer, 5, 371-376.
Lim, T., Lee, J., Lee, D., Lee, H., Han, B., Baek, K., … Kim, W. (2011). Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer. Cancer Chemotherapy and Pharmacology, 68, 255-262.
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008). Cancer-related inflammation. Nature, 454, 436-444.
Martin-Salces, M., de Paz, R., Canales, M. A., Mesejo, A., & Hernandez-Navarro, F. (2008). Nutritional recommendations in hematopoietic stem cell transplantation. Nutrition, 24, 769-775.
Meyerhardt, J., Catalano, P., Haller, D., Mayer, R., Macdonald, J., Benson A., III, & Fuchs, C. (2003). Impact of diabetes on outcomes in patients with colon cancer. Journal of Clinical Oncology, 21, 443-440.
Moien-Afshari, F., Ghosh, S., Khazaei, M., Kieffer, T. J., Brownsey, R. W., & Laher, I. (2008). Exercise restores endothelial function independently of weight loss or hyperglycaemic status in db/db mice. Diabetologia, 51, 1327-1337. doi:10.1007/s00125-008-0996-x
Moretti, M., Bennett, J., Tornatore, L., Thotakura, A. K., & Franzoso, G. (2012). Cancer: NF-kappaB regulates energy metabolism. International Journal of Biochemistry and Cell Biology, 10, 10.
Naing, A., Kurzrock, R., Burger, A., Gupta, S., Lei, X., Busaidy, N., … LoRusso, P. (2011). Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clinical Cancer Research, 17, 6052-6060.
Okabe, S., Ishikawa, T., Tanami, H., Kuwabara, H., Fukahara, T., Udagawa, M., … Iwai, T. (2002). Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer. Journal of Medical and Dental Sciences, 49, 77-84.
Psarakis, H. (2006). Clinical challenges in caring for patients with diabetes and cancer. Diabetes Spectrum, 19, 157-162.
Ribeiro, A. F., Camara, C., Segre, C. A., Srougi, M., & Serrano, C. V., Jr. (2010). Cardiovascular risks of androgen deprivation therapy. Arquivos Brasileiros De Cardiologia, 95, 412-415.
Richardson, L., & Pollack, L. (2005). Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nature Clinical Practice Oncology, 2, 48-53. doi:10.1038/ncponc0062
Roumen, C., Blaak, E. E., & Corpeleijn, E. (2009). Lifestyle intervention for prevention of diabetes: determinants of success for future implementation. Nutrition Reviews, 67, 132-146.
Spigel, D. R., Greco, F. A., Meluch, A. A., Lane, C. M., Farley, C., Gray, J. R., … Hainsworth, J. D. (2010). Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction. Journal of Clinical Oncology, 28, 2213-2219. doi:10.1200/jco.2009.24.8773
Stookey, J. D., Pieper, C. F., & Cohen, H. J. (2004). Hypertonic hyperglycemia progresses to diabetes faster than normotonic hyperglycemia. European Journal of Epidemiology, 19, 935-944.
Storey, S., & Von Ah, D. (2012). Impact of malglycemia on clinical outcomes in hospitalized patients with cancer: A review of the literature. Oncology Nursing Forum, 39, 458-465. doi:10.1188/12.ONF.458-465
Turina, M., Christ-Crain, M., & Polk, H., Jr. (2006). Diabetes and hyperglycemia: Strict glycemic control. Critical Care Medicine, 34 (9, Suppl.), S291-S300.
Zeng, L., Biernacka, K., Holly, J., Jarrett, C., Morrison, A., Morgan, A., … Perks, C. (2010). Hyperglycaemia confers resistance to chemotherapy on breast cancer cells: the role of fatty acid synthase. Endocrine-Related Cancer, 17, 539-551. doi:10.0677/ERC-09-0221